CEO of Aerie Pharmaceuticals provides a brief company overview at OIS meeting

Vince Anido, Chairman & Chief Executive Officer of Aerie Pharmaceuticals, Inc., provides an update on the company's glaucoma drugs at the Ophthalmology Innovation Summit (OIS) meeting during the annual American Society of Retina Specialists (ASRS) conference in Vancouver, British Columbia, on July 20th, 2018.

Related Videos
DAVIO trial update: 12-month safety results indicate no serious adverse events, reduced treatment burden
Phase 4 Paladin finds fluocinolone to be safe, effective in patients with diabetic macular edema
Foundation Fighting Blindness: Building a toolbox of therapies for dry AMD, inherited retinal diseases
Faricimab for DME: Personalized treatment interval dosing maintains visual acuity, reduces treatment burden
Diabetic retinopathy eye drop: Phase 1B clinical results show promise
Quicker time to surgery affects VA outcomes in macula-on rhegmatogenous retinal detachments
Giant retinal tear-related detachments: Pediatric eyes repair better after vitrectomy with scleral buckling; adults only need vitrectomy
KALAHARI study: Phase 2 early results indicate alternative treatment pathway for patients with DME is effective, durable
Elevated albumin to creatinine ratio associated with central subfield thickness fluctuations in patients with DME
RGX-314 demonstrates DRSS improvements in patients with DME, NPDR
Related Content
© 2023 MJH Life Sciences

All rights reserved.